{"schema_version":"secwatch.filing_event.v1","accession":"0001021771-21-000087","form_type":"8-K","ticker":"BRTX","cik":"0001505497","company_name":"BioRestorative Therapies, Inc.","filed_at":"2021-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.785724+00:00","generated_at":"2026-06-28T11:25:59.797250+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioRestorative Therapies prices $23M public offering, uplists to Nasdaq; appoints CFO and new directors","bullets":["Priced underwritten public offering of 2.3M units at $10/unit for gross proceeds of $23M; net proceeds ~$20.87M.","Common stock begins trading on Nasdaq Capital Market under symbol BRTX on November 5, 2021.","Appointed Robert E. Kristal as CFO; granted option for 10,490 shares at $13.50; also elected Patrick F. Williams and David Rosa as directors.","Granted options to officers and directors: Alstodt and Silva each received 42,059 shares; also repriced their existing options from $47.60 to $13.50.","Intends to use proceeds for clinical trials of BRTX-100, ThermoStem R&D, and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001021771-21-000087","json":"https://secwatch.observer/filing/0001021771-21-000087.json","markdown":"https://secwatch.observer/filing/0001021771-21-000087.md","text":"https://secwatch.observer/filing/0001021771-21-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/0001021771-21-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/form8kdtd110421.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T11:25:59.797250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ca43aec2b","claim":"David Rosa was elected as Director at BioRestorative Therapies, Inc..","evidence_excerpt":"Effective November 4, 2021, David Rosa was elected a director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/0001021771-21-000087-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"769a2b586a","claim":"Patrick F. Williams was elected as Director at BioRestorative Therapies, Inc..","evidence_excerpt":"Effective November 4, 2021, Patrick F. Williams was elected a director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/0001021771-21-000087-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ce8d3b1dfc","claim":"Robert E. Kristal was appointed as Chief Financial Officer at BioRestorative Therapies, Inc..","evidence_excerpt":"Effective November 4, 2021, Robert E. Kristal, age 54, was appointed Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/0001021771-21-000087-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}